BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 15948115)

  • 21. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
    Hinselwood DC; Abrahamsen TW; Ekstrøm PO
    Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
    Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
    Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens.
    Willmore-Payne C; Layfield LJ; Holden JA
    Cancer; 2005 Jun; 105(3):165-70. PubMed ID: 15822120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma.
    Hookim K; Roh MH; Willman J; Placido J; Weigelin HC; Fields KL; Pang J; Betz BL; Knoepp SM
    Cancer Cytopathol; 2012 Feb; 120(1):52-61. PubMed ID: 21793228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS; Ghoreschi K; Sander CA; Röcken M
    Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.
    Jarry A; Masson D; Cassagnau E; Parois S; Laboisse C; Denis MG
    Mol Cell Probes; 2004 Oct; 18(5):349-52. PubMed ID: 15294323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T1799A BRAF mutations in conjunctival melanocytic lesions.
    Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
    Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
    Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.